This study indicates a substantial increase in the number of economic evaluation studies on a diverse range of pharmacological, non-pharmacological, diagnostic, and preventive dementia interventions conducted between 2018 and 2022 compared with previous research in the field; however, the studies are restricted to a limited number of countries. |
Moreover, the quality of methodology and reporting of these studies, similar to the most recent reviews in this area, exhibits significant weaknesses that should be addressed by researchers to enhance the quality and rigour of future studies. |
1 Introduction
2 Methods
2.1 Literature Search
2.2 Inclusion and Exclusion Criteria
2.3 Selection of Studies and Data Extraction
2.4 Quality Assessment of Decision-Analytic Models
2.5 Narrative Analysis of Findings
3 Results
3.1 Search Results
3.2 Study Characteristics
3.2.1 Population, Country of Study, Interventions, and Study Perspective and Setting
No. | First author | Country | EE and model type | Intervention | Health condition | Perspective | Health outcomes | Converted ICER to 2023 US$ for cost-effective option |
---|---|---|---|---|---|---|---|---|
1 | Tullberg [50] | Sweden | CUA Markov (cohort) | Preventive (secondary) | iNPH | Societal | QALYs | $784.19/life-years saved $980.24/QALY |
2 | Michaud [40] | USA | CUA Markov (cohort) | Diagnostic + pharmacological | MCI | Healthcare sector and (modified) societal | QALYs | Societal perspective: No CSF biomarker testing and treatment for all MCI patients: $14,738.11/QALY CSF biomarker test and treat low-risk: $43,408.35/QALY Healthcare perspective Base-case scenario vs. CSF biomarker test and treat low-risk: $68,854.62/QALY |
3 | da Silva [30] | Brazil | CUA Markov (cohort) | Pharmacological (ChEIs) | AD | Healthcare sector | QALYs | Donepezil: $1940.82/QALY |
4 | Mar [31] | Spain | CUA DES (cohort) | Pharmacological: (medical food) | Early AD | Societal | QALYs (for both patients and caregivers) | Dominant |
5 | Yunusa [32] | USA | CUA Markov (cohort) | Pharmacological (ChEIs + NMDA) | AD (moderate-severe) | Healthcare payer (Medicare) | QALYs | Donepezil monotherapy vs. galantamine-memantine: $17,801.94 Rivastigmine transdermal patch vs. donepezil monotherapy: $99,232.09 |
6 | Synnott [41] | USA | CUA and CEA Markov | Pharmacological (anti-amyloid-β) | MCI | Healthcare sector and (modified) societal | QALYs, evLYG and life-years gained | Not cost effective |
7 | Wimo [49] | Finland and Sweden | CUA Markov (cohort) | Preventive (primary) | People at risk of dementia (no specific health condition) | (Modified) societal | QALYs | Extended dominance for the prevention strategy |
8 | Monfared [33] | USA | CUA Disease-simulation | Pharmacological (anti-amyloid-β) | AD (moderate-severe) | Payer perspective and societal | QALYs (for both patients and caregivers) | For a WTP threshold range of $50,000–$200,000/QALY, the potential annual VBP of lecanemab +SoC: Payer prc: $9636.02–$37,094.89 Societal prc: $10,835.19–$39,645.33 |
9 | Contador [42] | Spain | CEA Decision tree (cohort) | Diagnostic | MCI | Healthcare sector | Percentage of correctly diagnosed cases | Not cost effective |
10 | Ross [34] | USA | CUA Markov (cohort) | Pharmacological (anti-amyloid-β) | Early AD | Healthcare sector and societal | QALYs | Not cost effective |
11 | Kongpakwattana [35] | Thailand | CUA DES (cohort) | Pharmacological (ChEIs) | AD | Healthcare sector and societal | QALYs (exclusion of caregiver QOL regarding no difference in values for patients and caregivers) | Societal perspective: Donepezil with all disease-severity levels: $12,560.95/QALY |
12 | Vandepitte [51] | Belgium | CUA Markov (cohort) | Non-pharmacological (ADLs) | Informal caregivers of persons with dementia | Third-party payer perspective and societal | QALYs | Third-party payer: €12,183.45/QALY Societal: €11,709.16/QALY |
13 | Mesquida [45] | Spain | CUA Markov (cohort) | Pharmacological (managed care): Structured, patient-centred medication review by a multidisciplinary team aimed at reducing inappropriate psychotropic drug prescriptions based on a therapeutic guideline (standard care) | People with dementia | Healthcare sector | QALYs | Dominant |
14 | Lee [43] | South Korea | CUA Markov | Diagnostic: Amyloid-PET (care as usual) | MCI | Healthcare sector | QALYs | Not cost effective |
15 | Whittington [36] | USA | CUA and CEA Markov (cohort) | Pharmacological (anti-amyloid-β): Aducanumab + supportive care (supportive care alone) | Early AD | Healthcare sector and (modified) societal | QALYs (patients and caregivers), evLYG and LYG | Not cost effective |
16 | Zala [37] | UK | CUA Markov (cohort) | Pharmacological (ChEIs and NMDA): (1) Optimal treatment (NICE-recommended pharmacological therapy): Memantine (2) Suboptimal treatment: AChEIs alone or no treatment (no AChEIs)a | AD | Healthcare sector and societal | QALYs | Not detailed |
17 | Lin [38] | Taiwan | CUA Markov (cohort) | Preventive (primary): Immunotherapy (non-vaccination) | AD | Societal | QALYs | Not detailed |
18 | Önen [39] | USA | CUA Markov | Diagnostic: Screening policy (no screening policy) | AD | Healthcare sector | QALYs | Not cost effective |
19 | Baker [44] | Canada | CBA Not specified | Non-pharmacological (cognitive): Community-based memory intervention programme (standard of care) | Older adults with memory concerns | Healthcare sector | Health service utilization reduction costs averted by the intervention | Not applicable |
20 | Christensen [48] | USA | CUA Decision tree (cohort) | Diagnostic: IVF with a pre-implantation genetic testing strategy (unassisted conception with prenatal diagnosis) | Couples with one heterozygous Huntington disease individual | Societal | QALYs | Dominant |
21 | Knapp [47] | England | CUA Micro- and macrosimulation | Non-pharmacological (cognitive): CST (MCST+CST) | People with mild or moderate dementia | Healthcare sector | QALYs | CST: $21,207.96/QALY CST+MCST: $33,477.13/QALY |
22 | McRae [52] | Australia | CUA Not specified | Preventive (primary): BBL-GP programme (no intervention) | Not specified (older adults aged between 60 and 64 years) | Societal | QALYs | BBL-GP programmeb: $1927.41/QALY |
23 | Thanh [46] | Canada | CBA Decision tree (cohort) | Non-pharmacological (integrated): The PHC IGSI (no intervention) | People with dementia | Healthcare sector | Health service utilization reduction costs averted by the intervention | Not applicable |
3.2.2 Economic Evaluation Methods, Utilities, and Utilized Software for Modellings
No. | Study design | Country | Valuation method | Method of administration | Utilized state and score in the included study |
---|---|---|---|---|---|
1 | A cross-sectional study of 36 patients with idiopathic normal pressure hydrocephalus [88] | Sweden | Indirect valuation: EQ-5D | Proxy-reported | Improve (0.71), complication, deteriorated, and natural history (0.57) |
2 | a) A cross-sectional study [56] | US | Indirect valuation: HUI-II questionnaire | Proxy-reported | MCI (0.73) |
b) A cross-sectional study of 528 caregivers of AD patients [55] | US | Indirect valuation: HUI-II questionnaire | Proxy-reported | Mild AD (0.68 for community, 0.71 for NH), moderate AD (0.54 for community, 0.48 for NH) and severe AD 0.37 for community, 0.31 for NH) | |
3 | a) A cross-sectional study of 216 AD patients and 216 caregivers [89] | Canada and USA | Indirect valuation: EQ-5D questionnaire | Self-reported | Mild AD with NH (0.695) and moderate AD with NH (0.510), severe AD with NH (0.340) Mild AD with AChEI (0.774) Moderate AD with AChEI (0.510) Severe AD with AChEI (0.457) |
b) A cross-sectional study of 233 patients with AD [58] | Sweden | Indirect valuation: | Proxy-reported | ||
c) An observational study of 233 patients with AD and their primary caregiver (spouse or child of the patient in most cases) [90] | Multiple | Indirect valuation: EQ-5D questionnaire | Self- or proxy-reported | ||
d) A cross-sectional study of 60 mild-moderate AD patients and their caregivers [91] | Canada | HUI-III EQ-5D | Self- or proxy-reported | ||
4 | A cross-sectional study of 18,450 non-institutionalized Spanish population with a mean age of 50 years based on data from the Spanish Health Survey [92] | Spain | Indirect valuation: EQ-5D-5L questionnaire | Self-reported | Mild (0.52) and moderate (0.21) AD patients Mild (0.71) and moderate (0.65) AD caregiver |
A cross-sectional study of 237 patients with AD receiving outpatient care [93] | Spain | Indirect valuation: EQ-5D questionnaire QoL-AD instrument | Proxy-reported | MCI for patients and caregivers (utility scores vary depending on age) | |
5 | A cross-sectional study of 679 AD-affected person caregiver pairs was conducted at 13 community and institutional sites [94] | USA | Indirect valuation: HUI-II questionnaire | Proxy-reported | Moderate (0.54) and severe (0.37) AD |
6 | See 2a [56]a | See 2a | See 2a | See 2a | See 2a |
See 2b [55] | See 2b | See 2b | See 2b | See 2b | |
7 | A cross-sectional postal survey of 4950 individuals from the general population aged 20–88 years [95] | Sweden | Indirect valuation: EQ-5D questionnaire | Self-reported | At-risk (utility scores vary depending on age) |
See 3b [58] | See 3b | See 3b | See 3b | See 3b | |
8 | A fixed-effect meta-analysis using studies from a systematic literature review [96] | Multiple | Indirect valuation: EQ-5D questionnaire | Self- or proxy-reported | MCI (0.80), mild (0.74), moderate (0.59) and severe (0.36) AD |
See 3b [58] | See 3b | See 3b | See 3b | See 3b | |
9 | Not applicable | ||||
10 | A cross-sectional study of 679 AD patient/caregiver pairs [57] | USA | Indirect valuation: HUI-II questionnaire | Proxy-reported | MCI (0.73), mild (0.69), moderate (0.53) and severe (0.34) AD |
11 | A cross-sectional study of 148 community-dwelling patients aged ≥60 years [97] | Thailand | Indirect valuation: EQ-5D-5L questionnaire | Self-reported | Mild to moderate (varied depending on patients’characteristics) |
12 | See 2a [56] | See 2a | See 2a | See 2a | See 2a |
13 | See 4b [93] | See 4b | See 4b | See 4b | See 4b |
14 | Not detailedb [98] | South Korea | Indirect valuation: EQ-5D-3L questionnaire | Not detailed | Clinically normal (age ≥65 years; 0.874) MCI (0.80), mild (0.43), moderate (0.21) and severe (0.17) AD |
15 | See 2aa [56] | See 2a | See 2a | See 2a | See 2a |
16 | Mapped from HSQ-12, the Ferm's D–test and QoL–AD [99] | UK | Indirect valuation: EQ-5D questionnaire | Not detailed | Pre-full-time care (suboptimal treatment, optimal treatment), full-time care, deathc |
17 | See 2b [55] | See 2b | See 2b | See 2b | See 2b |
18 | See 2a [56] | See 2a | See 2a | See 2a | See 2a |
19 | Not applicable | ||||
20 | Not detailed (not referenced to source of publication) | ||||
21 | Systematic mapping of evidence | Multiple | Not detailed | Not detailed | Linked to CST, per person in the first year (0.03) |
An RCT on 236 participants with mild-to-moderate dementia who received CST for 7 weeks [100] | UK | Indirect valuation: EQ-5D questionnaire Dementia-specific measures (DEMQOL-U and DEMQOL-PROXY-U) | Proxy-reported | Linked to MCST per person in the first year (0.026) | |
22 | National health survey [101] | England | Indirect valuation: EQ-5D questionnaire | Not specified | Not specified |
Cross-sectional study of 488 people with a diagnosis of dementia according to DSM-IV criteria, along with their carers [102] | UK | Indirect valuation: EQ-5D questionnaire | Self- or proxy-reported | Not specified | |
23 | Not applicable |
3.2.3 Incorporated Health States, Time Horizon, Decision-Analytic Model Type and Cycle Length
No. | First author | Health states (if applicable) | Time horizon | Cycle length | Discount rate | Included costs | Sensitivity analysis |
---|---|---|---|---|---|---|---|
1 | Tullberg [50] | Four states: improved, complication, deteriorated, death for the shunt surgery pathway | Lifetime | NS | 0.03 for costs and effects | (1) Direct medical costs, including hospital inpatient and outpatient visits, shunt surgery, primary care physician visits, contacts with a physiotherapist, or nurse occupational therapist (2) Cost of residential care in nursing homes and home-help service costs (formal care) (3) Cost of care given by relatives in their spare time (informal care) after surgery or regarding natural history | Uni-DSA PSA |
2 | Michaud [40] | Four states: Mild, moderate, severe, death | Lifetime | 1 year | 0.03 for costs and effects | (1) Direct medical costs including medical costs and costs for medications (2) Informal healthcare costs, time costs of informal caregiving, home care, assisted living, and transport | Uni-DSA PSA SSA |
3 | da Silva [30] | Four states: Mild, moderate, severe, death | 10 years | 1 year | 0.05 for costs and effects | Direct costs, including the diagnostic tests (complete blood count, electrolytes, blood glucose, urea, creatinine, TSH, computed tomography and MRI, neuropsychological tests) and costs for medications | DSA PSA |
4 | Mar [31] | Four states: Prodromal, mild, moderate-severe, death | Lifetime | NA | 0.03 for costs and effects | (1) Direct costs, including healthcare costs and costs for medical food and diagnosing social care (2) Informal costs | Uni-DSA SSA |
5 | Yunusa [32] | Four states: Mild, moderate, severe, death | Lifetime | 1 year | 0.03 for costs and effects | (1) Direct medical, including costs for medications (2) Direct non-medical (3) Informal cost of caregiving | Uni-DSA PSA |
6 | Synnott [41] | Five states: MCI, mild, moderate, severe, death | Lifetime | 1 year | 0.03 for costs and effects | (1) Direct medical care costs, including drug costs, administration costs, cost of monitoring, and adverse event costs (2) Indirect costs of patient productivity impacts (3) Informal care costs, including caregiver direct medical costs and caregiver time costs | Uni-DSA PSA SSA |
7 | Wimo [49] | Five states: At-risk, mild, moderate, severe, death | Lifetime | 6 months | 0.03 for costs and effects | (1) Direct medical costs, including cost of health staff (nutritionist, physiotherapist, psychologist, nurse, physician, nutritionist), cost of Cognitive Training Programme development, cost of facilities (long-term institutional care, hospital care, home services) and cost of medicines (2) Informal care costs | Uni-DSA |
8 | Monfared [33] | Six states: MCI, mild, moderate, severe, institutional care, death | Lifetime | NS | 0.03 for costs and effects | 1) Direct medical costs relating to patient healthcare and screening costs (CSF, PET scan, monitoring costs, MRI unit cost) 2) Costs relating to patient social care 3) Indirect costs for caregiver informal care | Uni-DSA SSA |
9 | Contador [42] | Not specified | 3 months | NA | NA | (1) Direct healthcare costs, including medical visits and diagnostic procedures of amyloid-PET) and AD CSF biomarkers | Uni-DSA PSA |
10 | Ross [34] | Four states: MCI, mild, moderate, severe | Lifetime | 1 month | 0.03 for costs and effects | (1) Direct medical costs, including outpatient and inpatient care, medications, monitoring and infusions and costs regarding the adverse effects (2) Cost of home care and long-term care such as background care screening work-up (3) Indirect costs of informal caregiving | Uni-DSA PSA SSA |
11 | Kongpakwattana [35] | Not specified | 10 years | NA | 0.03 for costs and effects | (1) Direct medical costs, including costs associated with outpatient, inpatient, and emergency visits; medications; and out-of-pocket payments (2) Direct non-medical costs, including transportation and formal caregiving services used (3) Unpaid informal caregiving time and services | Uni-DSA PSA |
12 | Vandepitte [51] | Three states: Remain at home, institutionalized, death | 5 years | 6 months | 0.03 for costs and 0.15 for effects | (1) Direct medical (2) Non-medical costs, including residential (hospitalization and emergency consults) and community-based healthcare costs (outpatient visits, home help, and accommodation exclusive of patient co-payments (3) Informal care, non-health-care costs, and patient and caregiver co-payments | Uni-DSA PSA SSA |
13 | Mesquida [45] | Three states: Baseline health, deteriorated health, death | 1 year | NS | NA | (1) Direct costs, including medical visits, hospital care, medical tests and examinations and drugs administered | NS |
14 | Lee [43] | Seven states: Clinically normal, amyloid positivity, amyloid negativity, mild, moderate, severe, death | Lifetime | 3 months | 0.05 for costs and effects | 1) Direct medical costs 2) Direct non-medical costs, time and travel costs for both patients and caregivers 3) Informal care costs, including caregivers’ long-term care costs | Uni-DSA |
15 | Whittington [36] | Five states: MCI, mild, moderate, severe, death | Lifetime | 1 year | 0.03 for costs and effects | (1) Direct medical costs (administration costs, monitoring costs, adverse event costs, long-term costs), including payments by third-party payers, and patients’ out-of-pocket payments (2) Indirect costs, including labour market earnings lost and health-related cost items such as unpaid caregiver-time costs | Uni-DSA PSA SSA |
16 | Zala [37] | Four states: Pre-full-time care (suboptimal treatment, optimal treatment), full-time care, death | 5 years | 1 month | 0.035 for costs and effects | (1) Direct medical costs, including monthly costs of care for pre-full-time care and full-time care | NS |
17 | Lin [38] | Four states: MCI, mild, moderate, severe | 10 years | NS | 0.03 for costs and effects | (1) Direct costs included the medical expenses paid by National Health Insurance and out-of-pocket payments (2) Indirect costs mainly included caregiver time calculated by the opportunity cost of time and replacement cost | PSA |
18 | Önen [39] | Seven states: Cognitively normal, MCI without treatment, MCI with treatment, mild without treatment, moderate and severe, mild with treatment, death | Lifetime | 1 year | NS | (1) Direct medical costs (2) Informal treatment costs | Uni-DSA |
19 | Baker [44] | Not specified | Lifetime | NS | NS | (1) Administrative and programme expenses related to presenting the intervention | Uni-DSA |
20 | Christensen [48] | Events incorporated in the decision tree | 24 years | NS | 0.03 for costs and effects | All costs accrued regardless of payer | Uni-DSA PSA |
21 | Knapp [47] | Not specified | NS | NS | NS | (1) Direct costs included medication, hospital and community services (2) Costs for residential and daycare, equipment and adaptations (3) Informal care costs (unpaid care costs) were also considered | Uni-DSA |
22 | McRae [52] | Not specified | Lifetime | NS | 0.03 for costs and effects | (1) Direct medical costs product of the average annual costs of treatment/care and the duration of care | NS |
23 | Thanh [46] | Not specified | 1 year | NS | NA | (1) Direct medical costs, including intervention costs, outpatient clinic visits, emergency room visits or physician visits | PSA SSA |